120 related articles for article (PubMed ID: 15209436)
21. Predictive value of osteocalcin and beta-CrossLaps in metastatic breast cancer.
Salem AM; Zohny SF; Abd El-Wahab MM; Hamdy R
Clin Biochem; 2007 Nov; 40(16-17):1201-8. PubMed ID: 17889845
[TBL] [Abstract][Full Text] [Related]
22. The circadian rhythm of biochemical markers of bone resorption is normally synchronized in breast cancer patients with bone lytic metastases independently of tumor load.
Generali D; Berruti A; Tampellini M; Dovio A; Tedoldi S; Bonardi S; Tucci M; Allevi G; Aguggini S; Milani M; Bottini A; Dogliotti L; Angeli A
Bone; 2007 Jan; 40(1):182-8. PubMed ID: 16935041
[TBL] [Abstract][Full Text] [Related]
23. Characterization of aged osteocalcin fragments derived from bone resorption.
Cloos PA; Christgau S
Clin Lab; 2004; 50(9-10):585-98. PubMed ID: 15481635
[TBL] [Abstract][Full Text] [Related]
24. The use of bone markers in a 6-week study to assess the efficacy of oral clodronate in patients with metastatic bone disease.
Brown JE; McCloskey EV; Dewar JA; Body JJ; Cameron DA; Harnett AN; Ruutu M; Purohit OP; Tähtelä R; Coleman RE
Calcif Tissue Int; 2007 Nov; 81(5):341-51. PubMed ID: 17874331
[TBL] [Abstract][Full Text] [Related]
25. [Evaluation of cancer-induced bone diseases by bone metabolic marker].
Takahashi S
Clin Calcium; 2006 Apr; 16(4):581- 90. PubMed ID: 16582508
[TBL] [Abstract][Full Text] [Related]
26. Characterization of urinary degradation products derived from type I collagen. Identification of a beta-isomerized Asp-Gly sequence within the C-terminal telopeptide (alpha1) region.
Fledelius C; Johnsen AH; Cloos PA; Bonde M; Qvist P
J Biol Chem; 1997 Apr; 272(15):9755-63. PubMed ID: 9092508
[TBL] [Abstract][Full Text] [Related]
27. Development of a monoclonal antibody to urinary degradation products from the C-terminal telopeptide alpha 1 chain of type I collagen. Application in an enzyme immunoassay and comparison to CrossLaps ELISA.
Fledelius C; Kolding I; Qvist P; Bonde M; Hassager C; Reginster JY; Hejgaard J; Frøokiaer H; Christiansen C
Scand J Clin Lab Invest; 1997 Feb; 57(1):73-83. PubMed ID: 9127460
[TBL] [Abstract][Full Text] [Related]
28. [Beta-crosslaps].
Mori M
Nihon Rinsho; 2004 Dec; 62 Suppl 12():247-9. PubMed ID: 15658311
[No Abstract] [Full Text] [Related]
29. A new monoclonal antibody ELISA for detection and characterization of C-telopeptide fragments of type I collagen in urine.
Srivastava AK; MacFarlane G; Srivastava VP; Mohan S; Baylink DJ
Calcif Tissue Int; 2001 Dec; 69(6):327-36. PubMed ID: 11800229
[TBL] [Abstract][Full Text] [Related]
30. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis.
Chopin F; Garnero P; le Henanff A; Debiais F; Daragon A; Roux C; Sany J; Wendling D; Zarnitsky C; Ravaud P; Thomas T
Ann Rheum Dis; 2008 Mar; 67(3):353-7. PubMed ID: 17644538
[TBL] [Abstract][Full Text] [Related]
31. Isoaspartyl bond formation within N-terminal sequences of collagen type I: implications for their use as markers of collagen degradation.
Brady JD; Ju J; Robins SP
Clin Sci (Lond); 1999 Feb; 96(2):209-15. PubMed ID: 9918902
[TBL] [Abstract][Full Text] [Related]
32. Urinary markers of altered collagen metabolism in fibromyalgia patients.
Ribel-Madsen S; Christgau S; Gronemann ST; Bartels EM; Danneskiold-Samsøe B; Bliddal H
Scand J Rheumatol; 2007; 36(6):470-7. PubMed ID: 18092271
[TBL] [Abstract][Full Text] [Related]
33. Can bone markers guide more effective treatment of bone metastases from breast cancer?
Clemons M; Cole DE; Gainford MC
Breast Cancer Res Treat; 2006 May; 97(1):81-90. PubMed ID: 16319976
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic value of bone remodeling markers in the diagnosis of bone metastases in patients with breast cancer.
Pectasides D; Farmakis D; Nikolaou M; Kanakis I; Kostopoulou V; Papaconstantinou I; Karamanos NK; Economopoulos T; Raptis SA
J Pharm Biomed Anal; 2005 Feb; 37(1):171-6. PubMed ID: 15664758
[TBL] [Abstract][Full Text] [Related]
35. Racemization and isomerization of type I collagen C-telopeptides in human bone and soft tissues: assessment of tissue turnover.
Gineyts E; Cloos PA; Borel O; Grimaud L; Delmas PD; Garnero P
Biochem J; 2000 Feb; 345 Pt 3(Pt 3):481-5. PubMed ID: 10642505
[TBL] [Abstract][Full Text] [Related]
36. Urine products of bone breakdown as markers of bone resorption and clinical usefulness of urinary hydroxyproline: an overview.
Simsek B; Karacaer O; Karaca I
Chin Med J (Engl); 2004 Feb; 117(2):291-5. PubMed ID: 14975218
[TBL] [Abstract][Full Text] [Related]
37. A novel marker for assessment of liver matrix remodeling: an enzyme-linked immunosorbent assay (ELISA) detecting a MMP generated type I collagen neo-epitope (C1M).
Leeming Dj; He Y; Veidal S; Nguyen Q; Larsen D; Koizumi M; Segovia-Silvestre T; Zhang C; Zheng Q; Sun S; Cao Y; Barkholt V; Hägglund P; Bay-Jensen A; Qvist P; Karsdal M
Biomarkers; 2011 Nov; 16(7):616-28. PubMed ID: 21988680
[TBL] [Abstract][Full Text] [Related]
38. Excretion of collagen derived peptides is increased in women with stress urinary incontinence.
Kushner L; Mathrubutham M; Burney T; Greenwald R; Badlani G
Neurourol Urodyn; 2004; 23(3):198-203. PubMed ID: 15098214
[TBL] [Abstract][Full Text] [Related]
39. Bone resorption assessed by immunoassay of urinary cross-linked collagen peptides in patients with osteogenesis imperfecta.
Minisola S; Rosso R; Romagnoli E
J Bone Miner Res; 1995 Feb; 10(2):335-9. PubMed ID: 7754815
[No Abstract] [Full Text] [Related]
40. Urinary carboxyterminal telopeptide of collagen I as a potential marker of bone metastases chemotherapy monitoring in breast cancer.
Houzé P; Bellik B; Extra JM; Bouro F; Bousquet B
Clin Chim Acta; 1999 Mar; 281(1-2):77-88. PubMed ID: 10217629
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
